Northern Light Venture Capital
Edit

Northern Light Venture Capital

http://www.nlvc.com
Last activity: 04.06.2026
Active
Invests in categories: DataEdTechIndustryMobileOnlinePlatformProductProviderServiceTechnology
About NLVC

Founded in 2005, Northern Light Venture Capital (NLVC) is a leading venture capital firm specializing in early-stage enterprise technology, healthcare, and consumer technology companies. With $4.5 billion in capital under management, more than 300 investments and over 50 successful exits, NLVC partners with global entrepreneurs seeking China and global expansion opportunities, and helps build great, sustainable global companies that change society. NLVC is led by experienced entrepreneurs, operators, and investors with deep technical and global expertise in both China and the U.S.

Learn more at NLVC.com.
Portfolio
233
Mentions
23
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2005
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 233

DateNameWebsiteTotal RaisedLocation
26.09.2022Tangotango.cn-China, Sha...
26.09.2022Surpathsurpath.net-China, Sha...
13.09.2022CIMO Microcimomicro.com-China, Bei...
13.09.2022Becomingbcmdental.com-China, Gua...
15.08.2022Cardinal O...shanshu.ai-China, Bei...
28.05.2022BUDpointone.tech-China, Gua...
28.05.2022CATUGcatugbio.com-China, Gan...
28.05.2022BIOPSEEbiopsee.cn-China, Hub...
28.05.2022HemaCellxuejibio.com-China, Gan...
20.04.2022MemVergememverge.com$43.5MUnited Sta...
Show more

Mentions in press and media 23

DateTitleDescription
04.06.2026CRP advances Hong Kong IPO plan as it expands in industrial roboticsCRP Robot Technology, a Chengdu-registered robotics firm, filed an updated prospectus with the Hong Kong Stock Exchange on May 31 as it seeks a main board listing. Guotai Haitong Securities is the sole sponsor. The filing keeps CRP on track...
13.01.2026Spiro Medical Secures $67M to Revolutionize Asthma Treatment with PNM SystemSpiro Medical secured $67 million in Series A funding. This capital fuels development of its innovative Pulmonary Neuromodulation System (PNM). PNM offers a novel, drug-free approach for severe asthma. It uses mild electrical impulses to co...
12.01.2026Vibrant Therapeutics Raises $61M in FundingVibrant Therapeutics, a Guangzhou, China- and Cambridge, MA-based clinical-stage biotechnology company developing new therapeutics, raised $61M in new financing. The round included new investors Pfizer Ventures and Apricot Capital with part...
12.01.2026Vibrant Therapeutics: $61 Million Closed And Han Lee Named As Co-CEOVibrant Therapeutics, a clinical-stage biotech developing “logic-gated” therapeutics designed to activate selectively in diseased tissue, announced it has raised $61 million in new financing and appointed Han Lee, Ph.D. as co-chief executiv...
08.01.2026Spiro Medical: $67 Million Series Raised A To Develop Neuromodulation System For AsthmaSpiro Medical, a newly formed company focused on pulmonary neuromodulation for asthma, has closed a $67 million Series A equity financing to develop what it describes as a first-of-its-kind Pulmonary Neuromodulation System (PNM) for the tre...
07.01.2026Andera Partners Leads $67 Million Series A Financing in Spiro Medical to Develop a Neuromodulation System for Asthma.The financing included a syndicate of venture investors led by Andera Partners (Paris), Omega Funds (Geneva) and Sherpa Healthcare Partners (Cayman Islands) and joined by HSG (Hong Kong), Supernova Invest (Paris), Northern Light Venture Cap...
07.01.2026Spiro Medical Raises $67M in Series A FundingSpiro Medical, an Irvine, CA-based medtech company developing a pulmonary neuromodulation system (PNM) for the treatment of asthma, raised $67M in Series A funding. The round included a syndicate of venture investors led by Andera Partners ...
09.09.2025iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4...
09.09.2025iRegene Therapeutics Raises Series B+ FundingiRegene Therapeutics, a Chengdu, China-based biotechnology company developing chemically induced allogeneic cell therapy, raised an undisclosed amount in Series B+ funding. The round was led by Northern Light Venture Capital, Chuangjing Cap...
05.05.2025China’s PE-VC market braces for shakeup as tough times weed out trailing GPsThe ongoing reshuffle in Greater China’s private investment market is expected to intensify as significant macro challenges eliminate trailing managers with unwanted “zombie funds”.
Show more

Reviews 0

Sign up to leave a review

Sign up Log In